Trusted Resource for Clinical Trials, Protocols & Progress
Clinical trial outsourcing in India is regulated under the New Drugs and Clinical Trials Rules (NDCTR), 2019, administered by the Central Drugs Standard Control Organization (CDSCO). These rules have streamlined trial approvals, mandated ethics committee registrations, and introduced timelines for applications submitted by foreign and Indian sponsors.
Click to read the full article.
Risk-based monitoring in the UK reflects a shift towards proportionate, patient-centred trial oversight. By following a step-by-step approach—starting with structured risk assessments, developing RBM plans, leveraging digital tools, and ensuring CRO oversight—sponsors can meet MHRA and HRA expectations while optimising resources. RBM is now an essential element of modern UK clinical trials, balancing efficiency with participant safety.
Click to read the full article.
RWE strategies must adapt to:
Pediatrics: Registries capturing long-term pediatric safety data
Decentralized Trials: Wearables and telemedicine feeding real-world datasets
Cross-Border Data Use: Harmonization challenges across GDPR regimes
Post-COVID-19 Environment: Increased reliance on RWE due to disrupted trial conduct
Sponsors should: (1) implement robust GCP training programs; (2) strengthen monitoring oversight; (3) ensure real-time documentation; (4) audit CROs and vendors regularly; (5) conduct internal mock inspections; (6) use electronic systems with audit trails; (7) promptly address deviations with CAPA; and (8) maintain inspection readiness at all times.
Click to read the full article.
India’s PMS system is grounded in the Drugs and Cosmetics Act, 1940 and Rules, 1945, supported by Schedule Y and further reinforced by the New Drugs and Clinical Trials Rules (NDCTR), 2019. Together, these regulations define the scope, responsibilities, and procedures for PMS in the Indian context.
Click to read the full article.
Certain trials receive expedited timelines:
COVID-19 or public health emergency trials: Accelerated reviews possible
Pediatric trials: Summary results within 6 months
Rare disease trials: Often require flexible RFI handling due to limited data
Managing amendments effectively is essential for maintaining compliance in UK clinical trials. By distinguishing between substantial and non-substantial changes, following MHRA and HRA submission pathways, and keeping robust documentation, sponsors and investigators can navigate amendments smoothly. Strong planning and communication are key to avoiding inspection findings and ensuring trial continuity.
Click to read the full article.
Investigators should: (1) maintain GCP training; (2) document informed consent rigorously; (3) monitor protocol adherence; (4) ensure contemporaneous documentation; (5) maintain strict IMP accountability; (6) train and supervise staff; (7) engage in mock FDA audits; (8) implement robust CAPA systems; (9) ensure IRB approvals are current; and (10) maintain inspection readiness.
Click to read the full article.
The foundation of data integrity in clinical research stems from GCP principles and specific national and international guidance. In the Indian context, CDSCO, under the Ministry of Health and Family Welfare, governs clinical trials through the New Drugs and Clinical Trials Rules, 2019, in conjunction with the Drugs and Cosmetics Act & Rules.
Click to read the full article.
Pharmacovigilance obligations vary in complexity depending on trial type:
Oncology Trials: High SAE incidence requires robust reporting mechanisms.
Rare Diseases: Small cohorts make each adverse event impactful in benefit-risk assessments.
ATMPs: Long-term follow-up requirements extend PV obligations beyond trial completion.
Decentralized Trials: Remote monitoring increases reliance on digital reporting tools.
